Twenty years ago, our founding partners established DNDi – determined that a collaborative model of not-for-profit pharmaceutical R&D could deliver for neglected patients.
In 2022, our partnerships continued on our path of progress.
2022 in numbers
clinical trials in 8 disease areas, including 18 trials testing new chemical entities86
clinical trial sites in 28 countries3,242
patients enrolled in active DNDi clinical studies
R&D partner institutions in nearly 50 countries6:1
ratio of partner staff vs DNDi staff worldwide
people trained to support clinical research in Africa, Asia, and Latin America82%
of all R&D partner staff are based in low and middle-income countries (LMICs)5
research networks to strengthen research capacity in Africa, Asia, and Latin America
of DNDi leadership positions held by women70%
of peer-reviewed scientific articles on DNDi research had at least one author from a partner institution in an endemic country60%
of peer-reviewed scientific articles had a female first or last author
peer-reviewed scientific articles on DNDi research96%
of peer-reviewed scientific articles published in open-access journals
in annual expenditure€ 10.3 million
in in-kind contributions and collaborative funding from partners91%
of expenditure on social mission to maximize impact for neglected patients
projects in our R&D portfolio, and an additional 12 projects in the treatment access phase19
projects focused on identifying or developing new chemical entities
2022 in numbers
EXPLORE NOW: DNDi RESEARCH WORLWIDE
Active clinical sites
- Sleeping sickness
- Chagas disease
- Filaria: River blindness
- Hepatitis C
EARLY-STAGE RESEARCH SITES(Drug discovery and pre-clinical development)
RESEARCH PLATFORMS AND NETWORKSMap boundaries and borders do not reflect any position by DNDi on their legal status
Our cross-cutting commitments
Dr Irene Mukui
‘The neglect of women in R&D and access programmes for health is ubiquitous – we have normalized this neglect to the point that we scientists and clinicians accept exclusion of pregnant and breastfeeding women from our studies. We must intentionally address this neglect, or it will never change.’
‘Every day, across the globe, those caring for children have to struggle with the fact that many medicines given to the youngest ones are not child-friendly. In neglected diseases, children face double neglect. We need to prioritize children early in the research and development process to ensure their treatment needs are met with safe medicines in appropriate formulations.’
Head of Business Development and Decarbonization Roadmap Project Lead, DNDi
‘We made a serious commitment in our latest strategic plan to cut our carbon footprint. In 2022, we gathered the data to measure our baseline emissions globally and began the work of developing a quantitative roadmap that will guide us to reach a 50% reduction by 2030 compared to 2019 levels.’
‘Together with partners across multiple research areas, we are applying cutting-edge technology such as artificial intelligence to identify new compounds with the potential to become treatments that make a difference in patients’ lives.’
Anchored in our mission to respond to the medical needs of neglected populations, DNDi speaks out for the public policies and political will needed to ensure that all people benefit from medical innovation and have equitable access to the fruits of scientific progress.
Drawing lessons from our own experience, our teams spoke out in 2022 to push for open, transparent, and collaborative research and for equitable access to medicines and other health technologies.
A worldwide footprint anchored in endemic countries
91% of our expenditure in 2022 was for our social mission
A word of thanks
DNDi has now delivered 12 new treatments for six neglected diseases.
Every contribution is essential to advancing DNDi’s mission and goals.
We are deeply grateful to our donors and partners for their support in 2022.
Photo credits: Matt Bouch-DNDi; Manon Voland-DNDi; Ariane Mawaffo-DNDi; Ana Ferreira-DNDi; Sydelle Willow Smith-DNDi; Diogo Galvão-DNDi; Yaw Afrim Gyebi-DNDi; Xavier Vahed-DNDi; Scholars-DNDi; Kim Cloete-DNDi; Mercy Mumo-DNDi; Lameck Ododo-DNDi; Abang Amirrul Hadi-DNDi; Luke Duggleby-DNDi
Get our latest news, personal stories, research articles, and job opportunities.